PALO ALTO, Calif., June 25, 2020 /PRNewswire/
-- Long-term results of the Stereotactic
Ablative Radiotherapy for Comprehensive Treatment of
Oligometastatic Cancers (SABR-COMET) study published June 2, 2020 in the Journal of Clinical
Oncology showed positive increases in overall survival for
patients with multiple sites of metastasis when treated with
stereotactic ablative radiotherapy (SABR) versus
standard-of-care.1 Through the extended
follow-up, the impact of SABR on overall survival was larger in
magnitude than in the study's initial analysis published last year
in The Lancet.2
"The durability of the randomized data indicates a paradigm
shift in our approach to the treatment of patients with low burden
metastatic disease," commented senior study author Suresh Senan, MRCP, FRCR, PhD, Professor of
Radiation Oncology at the Amsterdam University Medical Centres in
Amsterdam, the
Netherlands. "These data add to a growing body of evidence
that supports the use of SABR as an ablative therapy for
oligometastatic cancers."
As outlined in the latest study results, patients in the
international randomized phase II trial who received SABR
demonstrated a 22-month improvement in 5-year median overall
survival compared with patients who received a standard-of-care
approach alone, corresponding to an absolute survival benefit of
24.6%.3 This is a marked improvement from the
results of the initial analysis2 in which the patients
receiving SABR demonstrated a 13-month improvement in median
overall survival over the control group.
"The size of the effect on long-term survival in this seminal
study marks a step-change in the way clinicians should treat
metastases from the highest incidence cancers," said Ricky Sharma, MD, PhD, vice president of
Clinical Affairs at Varian (NYSE: VAR). "With over one million
stereotactic body radiotherapy cases treated on TrueBeam®
alone, Varian continues to invest heavily to incorporate artificial
intelligence, extraordinary precision, and unrivalled patient
workflow into our industry leading delivery platforms for
radiosurgery. We believe our continued pursuit of innovation and
investment will ultimately help change the trajectory of cancer
outcomes for all patients."
While systemic therapy, including chemotherapy, has been offered
to patients with multiple metastases, the SABR-COMET data add to
the growing body of evidence that suggests the addition of
non-invasive treatments such as SABR can improve long-term outcomes
for patients. Phase III randomized trials are ongoing to confirm
the magnitude of the survival benefit for patients with a variety
of metastatic cancers, including the international, multi-center
SABR-COMET-3 clinical trial funded by Varian.
Mirroring the most common cancers treated across the world,
primary tumor types in the study were breast, lung, colorectal and
prostate. All patients enrolled had one to five new metastatic
lesions. Although patients treated with radiotherapy were 20% more
likely to suffer adverse events, there was no long-term impairment
of quality of life. The study further showed that even with
SABR, patients may progress with new metastases, likely due to the
presence of micrometastatic disease, but that some can receive
salvage therapy with repeat SABR.
About Varian
At Varian, we envision a world without
fear of cancer. For more than 70 years, we have developed, built
and delivered innovative cancer care technologies and solutions for
our clinical partners around the globe to help them treat millions
of patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 10,000 employees across 70 countries
keep the patient and our clinical partners at the center of our
thinking as we power new victories in cancer care. Because, for
cancer patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow @VarianMedSys
on Twitter.
Press Contact
Aimee
Corso
Health + Commerce
+1 (310) 780-2661
aimee@healthandcommerce.com
Investor Relations Contact
Anshul Maheshwari
Vice President, Investor Relations
+1 (650) 424-5631
investors@varian.com
1 J Clin Oncol 2020 Jun
2;JCO2000818 doi: 10.1200/JCO.20.00818
2 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32487-5/fulltext
3 J Clin Oncol 2020 Jun 2;JCO2000818 doi:
10.1200/JCO.20.00818
View original
content:http://www.prnewswire.com/news-releases/long-term-results-from-sabr-comet-further-demonstrate-effectiveness-of-stereotactic-ablative-radiotherapy-for-comprehensive-treatment-of-metastatic-cancers-301083479.html
SOURCE Varian